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A simple method to measure 
sulfonation in man using 
paracetamol as probe drug
Natália Marto 1,2*, Judit Morello1,3, Alexandra M. M. Antunes3, Sofia Azeredo4, 
Emília C. Monteiro1,5 & Sofia A. Pereira1,5
Sulfotransferase enzymes (SULT) catalyse sulfoconjugation of drugs, as well as endogenous 
mediators, gut microbiota metabolites and environmental xenobiotics. To address the limited 
evidence on sulfonation activity from clinical research, we developed a clinical metabolic phenotyping 
method using paracetamol as a probe substrate. Our aim was to estimate sulfonation capability 
of phenolic compounds and study its intraindividual variability in man. A total of 36 healthy adult 
volunteers (12 men, 12 women and 12 women on oral contraceptives) received paracetamol in a 
1 g-tablet formulation on three separate occasions. Paracetamol and its metabolites were measured 
in plasma and spot urine samples using liquid chromatography-high resolution mass spectrometry. 
A metabolic ratio (Paracetamol Sulfonation Index—PSI) was used to estimate phenol SULT activity. 
PSI showed low intraindividual variability, with a good correlation between values in plasma and spot 
urine samples. Urinary PSI was independent of factors not related to SULT activity, such as urine pH 
or eGFR. Gender and oral contraceptive intake had no impact on PSI. Our SULT phenotyping method 
is a simple non-invasive procedure requiring urine spot samples, using the safe and convenient drug 
paracetamol as a probe substrate, and with low intraindividual coefficient of variation. Although it 
will not give us mechanistic information, it will provide us an empirical measure of an individual’s 
sulfonator status. To the best of our knowledge, our method provides the first standardised in vivo 
empirical measure of an individual’s phenol sulfonation capability and of its intraindividual variability. 
EUDRA-CT 2016-001395-29, NCT03182595 June 9, 2017.
The cytosolic sulfotransferase enzymes (SULT) are products of a diverse gene superfamily that catalyse sulfocon-
jugation (or sulfonation)—a relatively understudied topic in the area of drug metabolism—using 3′-phospho-
adenosine 5′-phosphosulfate (PAPS) as a sulfate donor. First-pass effect organs, such as the liver and the small 
intestine, contain the largest overall amount of SULT, while the kidney and lung contain low levels of  SULT1. 
Besides involvement in drug metabolism, SULT are at the crossroad of metabolic pathways of endogenous 
compounds (e.g. estradiol, thyroid hormones, catecholamines), diverse environmental xenobiotics and even 
human-gut microbiome metabolites (e.g. cresols and indoles), all with the potential to compete for sulfonation 
and reciprocally influence  biotransformation2,3.
Among SULT involved in xenobiotic and drug biotransformation, SULT1A1 is particularly relevant, due to its 
broadest substrate specificity and extensive tissue distribution, being the major enzyme in the  liver2. SULT1A1 
catalyses with high affinity sulfonation of many phenolic molecules, including estradiol and thyroid hormones, 
several environmental mutagens and carcinogens, gut microbiome metabolites, and drugs (e.g. paracetamol, 
ethinylestradiol, levodopa, opioid drugs, propofol, tedizolid, fulvestrant, and tamoxifen’s active metabolites)4–7.
Another SULT important in drug metabolism is SULT1A3, which is specific to primates and catalyses the 
sulfonation of catecholamines and drugs such as salbutamol, paracetamol, morphine, tramadol metabolites, 
tapentadol, levodopa, and  troglitazone2,8–11. In adults, SULT1A3 is a major extrahepatic enzyme, particularly 
abundant in the small intestine, with implications for the oral bioavailability of a number of drugs and dietary 
compounds that are its  substrates12.
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Race-related genetic variation in SULT enzymes includes single nucleotide polymorphisms and copy num-
ber variation, which have been shown to significantly determine enzyme  activity13,14. Nevertheless, genetic 
variation only explains a minor part of interindividual variability, suggesting regulation by nuclear receptors, 
PAPS-cofactor availability and inhibition by various drugs and environmental compounds could be major deter-
minants of variability in SULT  activity15. This variability in sulfonation capacity may determine therapeutic 
failure or toxicity of drugs metabolized by SULT, underlie drug interactions and interfere with the metabolism 
of environmental and dietary chemicals or endogenous compounds, with possible implications in disease and 
uncharted adverse drug  reactions15.
In contrast to phase I enzymes, there is limited evidence on sulfonation activity from clinical research, 
although in vivo studies are of key importance in assessing the functional consequences of individual  variation16. 
Current knowledge on SULT interindividual variability is mostly based on animal studies and on in vitro phar-
macogenetic and expression/activity  studies15. These data are hampered by relevant interspecies differences in 
SULT expression and the technical difficulties in maintaining the activity of cytosolic enzymes in vitro2,15. Clinical 
evidence on SULT activity derives mostly from Rosemary Waring’s clinical studies on sulphur biotransforma-
tion pathways in specific chronic diseases, which introduced paracetamol as a probe drug to estimate sulfation 
 capacity17–22. Occasional epidemiological studies have focused on the associations between SULT genotype and 
cancer risk and treatment  response23.
In implementing precision medicine initiatives for SULT-mediated drug metabolism, we must identify 
methods that will likely produce accurate evidence of enzyme activities (phenotypes). As part of our group’s 
focus on precision  medicine24,25, particularly on the uniqueness of the individual’s metabolic capability and its 
implications for drug response, we strived to develop a simple method for estimating sulfonation capacity in 
the clinical setting.
Metabolic phenotyping is a well-established field involving the analysis of metabolites in body fluids using var-
ious spectroscopic methods to provide information on the metabolic phenotype of individuals or  populations26,27. 
The metabolic phenotype is the characteristic metabolite profile reflecting the host genome and its interaction 
with environmental factors, diet, and the gut microbiome, and can be used to analyse the relationships between 
genetic variations and environmental triggers of disease and to study drug  response26,28. Current research is using 
metabolic phenotype to describe real-time enzyme activity through the calculation of a product-to-substrate 
ratio for a particular enzyme of  interest29. In our case, we are calculating a sulfonated-metabolite to probe sub-
strate ratio.
Echoing RH Waring’s pioneering work, our clinical metabolic phenotyping method uses paracetamol as a 
probe substrate. Paracetamol is mostly metabolized by phase II reactions of biotransformation and its sulfona-
tion accounts for up to 35% of the total paracetamol metabolism in humans. (Fig. 1) In vitro studies have shown 
paracetamol sulfonation to be mediated by several SULT isoforms, including SULT1A1, SULT1A3, SULT1C4, 
SULT1E1 and  SULT2A110,30. Nevertheless, studies in human organ samples have shown that sulfonation of par-
acetamol occurs mainly in liver and small intestine, where SULT1A1 and SULT1A3 are particularly abundant, 
 respectively10. Although it has the highest affinity for paracetamol, SULT1C4 is primarily expressed in the foetal 
liver and in small quantities in lung and kidney, assuming a minor role in paracetamol metabolism in postnatal 
 life10,12. While SULT1E1 and SULT2A1 are capable of sulfonating paracetamol at high concentrations, these 
isoforms probably have irrelevant activity in vivo10. Hence, paracetamol sulfonation reflects mainly the activ-
ity of SULT1A1 and 1A3 and could be used as an estimate of the activity of these enzymes, to stratify patients 
according to their phenol sulfonation capability.
Here, we report the results of our pilot clinical study testing a simple experimental protocol and analytical 
method using a metabolite ratio after ingestion of paracetamol for assessment of phenol sulfonation phenotype 
Figure 1.  Paracetamol metabolism overview. P paracetamol, SULT sulfotransferase, UGT uridine 
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and analysis of intraindividual variability in healthy volunteers. To the best of our knowledge, so far there is no 
data on intraindividual variability for SULT activity in man.
Materials and methods
Ethics. The following protocol is approved by the Portuguese National Ethics Committee (CEIC code 
20160561) and the Institutional Review Board at Hospital da Luz, SA, Lisbon, Portugal (IRB protocol 
HL_001_2016). The study conforms to Declaration of Helsinki, European Medicines Agency Guidelines for 
Good Clinical Practice and local regulations and is registered at the European Union Drug Regulating Authori-
ties Clinical Trials Database (EUDRA-CT 2016-001395-29) and at ClinicalTrials.gov (NCT03182595). Written 
informed consent was obtained from all subjects.
Study population. Assuming SULT activity might vary between 0 and 60% and estimating standard devia-
tion (SD) as SD = range/431, with a margin of error of 5% (E = 0.05) and a confidence level of 95% (z = 1.96), we 
calculated a sample size of n = 35 (> 34,57). To allow for stratification by sex and by oral contraceptive use, we 
recruited 12 men and 24 women (12 on oral contraceptives).
We screened adult volunteers from the community: a thorough history was obtained from all the subjects 
and each subject had a physical examination, blood tests and, for women, a urine pregnancy test. Patients were 
excluded if they reported significant disease, were on regular medication or had intake of any medication within 
14 days before the beginning of the study (except for oral contraceptives). Subjects with a history of allergy or any 
contraindication to paracetamol were also excluded. Eligible subjects had screening blood tests within normal 
range and a negative pregnancy test.
Study design. Eligible subjects had baseline blood and urine sampling (visit 1) and a further run-in period 
that included three sampling moments (visits 2 through 4), once every four weeks. At each of these three visits, 
subjects received paracetamol in a 1 g-tablet formulation (Ben-U-Ron, Bene Farmacêutica Lda., Lisbon, Portu-
gal), to be taken orally with water, and had blood and urine samples collected 2 h after paracetamol intake; this 
time point was selected according to plasma concentration–time curves for paracetamol and its metabolites 
derived from published pharmacokinetic  studies32,33. Aliquots were taken and stored at − 80 °C until analysis.
Analytical procedures. The relative levels of paracetamol and its metabolites (glucuronide, sulfate, 
cysteinyl-S-conjugate and mercapturate) were assessed in plasma and urine using liquid chromatography-high 
resolution mass spectrometry (LC-HRMS). The pH was measured for all urine samples. Glomerular filtration 
rate (eGFR) was estimated for every subject using the CKD-EPI Creatinine 2009  Equation34.
Urine and plasma sample treatment and liquid chromatography‑high resolution mass spectrometry 
(LC‑HRMS). Urine and plasma samples were analysed separately, using the same methodology. Samples were 
randomized before extraction.
A volume of 10 µL of each sample were pooled (quality control pool) and processed together with the samples 
to check the performance of the sample treatment and the LC-HRMS acquisition. Samples were processed upon 
a protein precipitation  protocol35. Briefly, 150 µL of cold ethanol were mixed with 50 µL of sample. Samples were 
vortexed and placed at − 20 °C for 20 min. Then, samples were centrifuged at 3660 g for 10 min and 150 µL of the 
supernatant were transferred to a new microcentrifuge tube for dry vacuum. Dried samples were reconstituted 
with 10% acetonitrile in water: 400 µL in the case of urine or 150 µL in the case of plasma.
Samples were analysed by ultra-high-performance liquid chromatography (Elute UHPLC, Bruker, Bremen, 
Germany) interfaced with a Bruker Impact II quadrupole time-of-flight mass spectrometer equipped with an 
electrospray source (Bruker, Bremen, Germany). Chromatographic separation was performed on a CORTECS 
T3 column (1.6 µm, 2.1 × 100 mm) protected with a CORTECS T3 VanGuard pre-column (1.6 µm, 2.1 × 5 mm). 
The temperature of the column was set to 45 °C. The mobile phases consisted of water with 0.1% v/v of formic 
acid (phase A) and acetonitrile with 0.1% v/v of formic acid (phase B). The gradient was as follows: 0 min 100% 
phase A, then in 1 min 95% phase A, in 5 min 50% phase A, in 4 min 0% phase A, held for 8 min at 0% phase 
A, and then in 1 min to 100% phase A, held for 6 min at 100% phase A. The injection volume was 3 µL and the 
flow rate was 400 µL/min.
The high-resolution mass spectra were acquired in ESI positive mode, with the optimized parameters set as 
follows: ion spray voltage, + 4.5 kV; end plate offset, 500 V; nebulizer gas  (N2), 4 bars; dry gas  (N2), 8 L  min−1; dry 
heater 200 °C. Internal calibration was performed on the high-precision calibration mode (HPC) with a solution 
of sodium formate 10 mM introduced to the ion source via a 20 µL loop at the beginning of each analysis, using a 
six-port valve. Acquisition was performed in full scan mode in the m/z 50–1000 range with a spectra rate of 1 Hz.
For compound identification, pseudo-multiple reaction monitoring (pseudoMRM) experiments were per-
formed with the calculated exact m/z values of paracetamol and paracetamol metabolites (see Supplementary 
Tables S1 and S2 online). Besides, a paracetamol standard solution was injected to check the retention time of 
paracetamol.
Targeted peak detection of paracetamol and paracetamol metabolites. Paracetamol and paracetamol metabolites 
were identified from the expected m/z values of the precursor and product ions of paracetamol and paracetamol 
metabolites previously  described35,36. Both measured accurate m/z and mSigma values were annotated for each 
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The acquired LC–MS data files from visits V2, V3 and V4 (98 samples) were converted to *.mzXML files 
using the ProteWizard MSconvert  tool37. A targeted analysis was then performed with the open-source software 
 MZmine38,39 and consisted of target peak detection, correction of retention time and peak matching.
Targeted peak detection was performed with the list of the corresponding m/z and retention time values 
for each precursor compound (see Supplementary Table S1 online) and the following parameters: shape toler-
ance = 10%, noise level = 1000, m/z tolerance = 0.005 Da or 20 ppm and retention time tolerance = 0.25 – 0.50 min 
(depending on the sample due to a retention time shift). Peak matching among samples was performed using the 
Join aligner method with m/z tolerance = 0.005 Da or 20 ppm, retention time tolerance = 0.5 (plasma samples) or 
0.7 (urine samples) minute, weight for m/z and retention time = 1 and require same identification.
Phenotype assignment. Paracetamol sulfonation index (PSI) was used to express phenol SULT 
activity. Three ratios were evaluated as candidates for PSI, as follows: PS/P, PS/(P + PS + PG) and PS/
(P + PS + PG + PM + PC). All ratios were calculated for plasma and urine samples.
Data and statistical analysis. Before statistical analysis, data were normalized by the total area of the 
chromatographic peaks corresponding to paracetamol and the metabolites of paracetamol. Descriptive statis-
tics are presented as means and standard deviation. A P value less than 0.01 was considered to be statistically 
significant.
The demographic, background and baseline data are presented descriptively.
A frequency distribution analysis was performed for PSI. We calculated the intraindividual coefficient of vari-
ation (CV) expressed in percentage %. Correlation analysis was performed by calculating Pearson’s coefficient of 
correlation. The Kruskal–Wallis test was used to detect differences in PSI between groups.
All statistical analyses were performed using GraphPad Prism 7.0 software.
Ethics approval. The protocol is approved by the Portuguese National Ethics Committee (CEIC 
code 20160561)  and the Institutional Review Board at Hospital da Luz, SA, Lisbon, Portugal (IRB protocol 
HL_001_2016). The study conforms to Declaration of Helsinki, European Medicines Agency Guidelines for 
Good Clinical Practice and local regulations and is registered at the European Union Drug Regulating Authori-
ties Clinical Trials Database (EUDRA-CT 2016–001,395-29) and at ClinicalTrials.gov (NCT03182595).
Consent to participate. Written informed consent was obtained from all subjects.
Results
Thirty-six adults were enrolled in our study, including 12 men, 12 women on oral contraceptives and 12 women 
off oral contraceptives.  All subjects were self-reported as healthy and used no medication. Table 1 summarizes 
the clinical characteristics of the 36 included subjects. There were no significant differences between the three 
groups. All subjects completed phenotyping visits. Two subjects missed the appointments for two of the phe-
notyping visits.
Paracetamol concentrations varied between 5 and 500 mcg /mL in urine samples and between 1 and 100 
mcg /mL in plasma samples, values in accordance with the reported paracetamol concentrations in biological 
 samples33,40,41.
We analysed three different metabolic ratios: PS/PG, PS/(P + PS + PG) and PS/(P + PS + PG + PM + PC). Con-
sidering the three ratios, the ratio PS/(P + PS + PG) (hereafter referred to as PSI) resulted in the least amount of 
intraindividual variability. Although only the results for this ratio are reported, statistical analysis was performed 
for the three ratios, producing similar results (data not shown).
PSI distribution and variability. The frequency distribution histogram of plasma PSI (pPSI) and urinary 
PSI (uPSI) was positively skewed in the studied population (Fig. 2). The mean pPSI and uPSI were 0.43 (range 
0.34 to 0.60) and 0.40 (range 0.31 to 0.55) respectively.








Age (years) (mean and standard deviation) 34 (11) 35 (11) 34 (11)
Ethnic background: Caucasian 35/36 12/12 23/24
BMI (kg/m2) (mean and standard deviation) 22.9 (2.9) 24.3 (2.5) 22.2 (2.8)
Oral contraceptive (%) 33 NA 50
Current smoker (%) 22 25 21
Caffeine consumption (cups/day) (mean) 3 3 3
Alcohol consumption (glasses of wine/ day) (mean) 0.08 0.08 0.08
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Intraindividual variability. Figure 3 illustrates the PSI for 23 women and 11 men who underwent consecutive 
PSI measuring. Only one value is presented for the female subject and the male subject who had data collected 
out of phase because they missed their appointments.
No differences were found between men and women. Coefficients of intraindividual variation in PSI ranged 
from 2 to 33% in plasma and 2% to 28% in urine, with a mean value of 10% and 13%, respectively.
Influence of gender. Figure 4 illustrates the pooled PSI for men and for women, and no sex-dependent dispari-
ties were found, both in plasma and urine samples.
Influence of oral contraceptives. Figure 4 depicts the pooled values for women on and off oral contraceptives 
and there were no differences between groups, both in plasma and urine samples.
Relationship between PSI in urine and renal clearance. In order to investigate whether PSI values in 
urine were affected by renal clearance, we analysed the influence of glomerular function (estimated glomerular 
filtration rate—eGFR) estimated through the CKD-EPI 2019 Creatinine  Equation34 and passive reabsorption 
measuring urinary pH.
No correlation was found between PSI in urine and urine pH or eGFR.
Correlations among urinary and plasma measurements. No concordance was found between val-
ues of unchanged paracetamol in plasma and urine. However, a statistically significant correlation was found for 
all the individual metabolites (glucuronide, sulfate, cysteinyl-S conjugates and mercapturate) between plasma 
and urine. The Pearson’s correlation coefficient measuring the linear association between the two variables was 
lowest for PS (Pearson r = 0.61) and highest for PC (Pearson r = 0.84).
Figure 2.  Frequency histogram plotted as Paracetamol Sulfonation Index (PSI) for clinical phenotyping of 
SULT vs. number of individuals (n = 36). Abscissa denotes the metabolic ratio expressed as PSI, calculated from 
unchanged paracetamol and its sulfate and glucuronate conjugates, measured in plasma (A) and urine (B) 
samples using LC-HRMS, 2 h after ingestion of 1 g of paracetamol. We found a similar distribution of PSI for 
plasma (A) and urine (B) samples, revealing an identical mean and a right skew. Although the distribution is 
mostly uniform, individuals with higher sulfonation capacity may be singled out.
Figure 3.  Mean Paracetamol Sulfonation Index (PSI) for clinical phenotyping of SULT in 34 individuals. PSI 
was calculated from unchanged paracetamol and its sulfate and glucuronate conjugates, measured in plasma (A) 
and urine (B) samples using LC-HRMS, after ingestion of 1 g of paracetamol on three separate occasions. Data 
are mean and standard deviation (SD) calculated for every subject; only one value is presented for individuals 
No. 26 and No. 27, who missed two phenotyping visits.
6
Vol:.(1234567890)
Scientific Reports |         (2021) 11:9036  | https://doi.org/10.1038/s41598-021-88393-3
www.nature.com/scientificreports/
The correlation between plasma PSI and urinary PSI was also different from zero with statistical significance 
and the estimated Pearson’s correlation coefficient obtained was 0.79 (Fig. 5).
Tolerability of probe drug. Paracetamol was well tolerated in all administrations and no adverse events 
were considered related to the medicinal product.
Discussion
In this population of healthy adults, PSI showed low intraindividual variability, with a good correlation between 
values in plasma and spot urine samples. Urinary PSI was independent of factors not related to enzyme activ-
ity such as urine pH or eGFR. Gender and oral contraceptive intake had no influence on our metabolic ratio.
So far, studies on variability of SULT activity were carried in animals or in vitro2, using enzymatic activity or 
expression studies in cell cytosolic  fractions14. The few existing clinical studies estimating sulfonation capacity 
were focused on differences on sulphur metabolism across disease states, rather than on designing a validated 
method to measure SULT  activity17–22.
Compared to these previous studies of SULT activity, our work’s major innovation is the intent to measure 
sulfoconjugation in clinical context. To do so, we chose a metabolic phenotyping method. Metabolic profiling 
is now a well-accepted integrative approach to stratify patients according to the activity of drug metaboliz-
ing enzymes, sensitive to both genetic and environmental influences, and has been used extensively to study 
 cytochromes42. The same is not true among phase 2 enzymes, where N-acetyltransferase type 2 is the only one 
with an established probe  substrate43.
Paracetamol as a probe for the study of sulfonation. Others before us have used paracetamol to 
study sulfonation but with different purposes. In a seminal work on SULT from the 80’s, Reiter et al.  studied 
Figure 4.  Comparison of Paracetamol Sulfonation Index (PSI) for clinical phenotyping of SULT between men 
and women, on and off oral contraceptives. Data are mean and standard deviation of PSI calculated in plasma 
(A) and urine (B) samples for 12 men, 12 women off oral contraceptives and 12 women on oral contraceptives. 
No significant differences were found between the three groups.
Figure 5.  Correlation between Paracetamol Sulfonation Index (PSI) for clinical phenotyping of SULT 
measured in plasma and urine samples. We found a good correlation between plasma and urinary PSI (Pearson’s 
correlation coefficient = 0.79, p < 0.001).
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SULT enzymatic activity in platelet cytosols and its correlation with in vivo sulfate conjugation of paracetamol, 
concluding that variations in platelet SULT activity reflect individual variations in the urinary excretion of the 
sulfate conjugate of  paracetamol44. In the same decade, Bonham-Carter used a similar design to test the cor-
relation between SULT activity measured with different substrates and the in vivo conjugation of paracetamol 
and salicylamide in man, but came to a different conclusion: they found no significant relationship between 
the in vivo pattern of sulfoconjugation of either drug and the activity of platelet SULT assayed with  tyramine45. 
Throughout de 90s, Waring et al. produced vast literature devoted to studying variations in sulphur xenobio-
chemistry in pregnancy, circadian rhythm and several chronic diseases, including autism, migraine, inflamma-
tory arthritis, biliary cirrhosis and chronic neurological  diseases17–22,46,47. This team used paracetamol sulfate 
and the ratio PS/PG as an estimate of sulfation capacity, leading to breakthroughs such as scientific evidence 
suggestive of abnormal sulfur metabolism affecting people with autism spectrum disorders. Nevertheless, no 
intention was dedicated to validating the method. In a paper from 2009, Clayton et al., intent on investigating 
the prediction of drug response based on the predose urinary metabolite profile, chose paracetamol to exem-
plify this pharmacometabonomic approach; on doing so, they uncovered important interactions between sul-
fonation of xenobiotics and host microbiome  metabolites48. In 2019, Cook and co-authors, to demonstrate that 
SULT isoenzymes could be selectively inhibited for therapeutic purposes, administered both paracetamol and 
mefenamic acid (a known SULT1A1 inhibitor) to an adult healthy man and found that paracetamol sulfonation 
was substantially  decreased49.
Our choice of paracetamol as a probe drug proved to be a very convenient one, fulfilling all the necessary 
requirements for such a  compound43: a widely available, safe and inexpensive therapeutic drug; with rapid 
absorption upon oral administration and a short elimination half-life; and finally with a significant metabolism 
by SULT at therapeutic doses and a simple metabolic scheme. On the downside, paracetamol is not exclusively 
metabolized by SULT; nevertheless, it is directly sulfonated without a phase I intermediate and it has a sufficient 
degree of selectivity to SULT1A1 and SULT1A3. Moreover, as paracetamol is glucuronidated and sulfonated at 
therapeutic doses and oxidative metabolism is a minor contributor, it is a useful model compound for the study 
of phase II  conjugation50. So far, clinical research on metabolic phenotypes has been more focused on CYP450 
enzymes and evidence is needed for phase II enzymes.
The main isoforms involved in paracetamol metabolism in adults are SULT1A1 and  SULT1A310. Still, we know 
from previous studies that the production of paracetamol sulfate is not influenced to a significant extent by the 
route of administration (oral versus intravenous), implying there is little sulfonation in the gastrointestinal tract, 
supporting a principal role for the major hepatic isoform SULT1A1, rather than the major intestinal isoform 
SULT1A3, in the metabolism of paracetamol in vivo51. While using paracetamol as a probe substrate, we can 
assume that we are evaluating the SULT enzymes involved in metabolizing orally administered phenolic drugs, 
predominantly the activity of SULT1A1, the main SULT isoform in drug metabolism.
PSI as a metric for the study of sulfonation. By administering a fixed dose of paracetamol to subjects, 
we could measure the concentration of the drug and its metabolites and build a formula to infer the activity of 
phenol SULT: Paracetamol Sulfonation Index (PSI). This metric offers several desirable qualities. First, the met-
ric appears sensitive enough to discriminate between subjects with higher and lower phenol sulfonation capacity, 
as we can observe from the frequency histogram.
Secondly, PSI both in plasma and urine showed a low intraindividual coefficient of variation suggesting high 
individual stability of SULT activity and good reproducibility of our ratio. This is of outstanding importance for 
a phenotyping  metric52.
Thirdly, our metric revealed good correlation between values in plasma and urine. So, for further studies we 
can use the metabolic ratio in urine spot samples due to the non-invasiveness and ease of sampling.
Finally, urinary PSI does not depend on factors not related to enzyme activity such as urinary pH and renal 
function; this is line with the reports of the renal clearance of paracetamol and the highly polar glucuronide and 
sulfate conjugates, rapidly excreted by the kidney without reabsorption, being relatively insensitive to variations 
in urine flow, urine pH and kidney  function32.
The accuracy with which our probe drug metric, PSI, indeed reflects the activity of phenol SULT is difficult 
to scrutinize since there are no other validated metrics for SULT activity in vivo and there is poor correlation 
between in vitro and in vivo  activity45. Providentially, the evidence collected by Cook and co-authors in 2019 by 
co-administering paracetamol and mefenamic acid to an adult male implicitly validates our metric: they proved 
that a known SULT1A1 inhibitor reduced the generation of paracetamol sulfate, so we can infer PSI is sensitive 
to enzymatic inhibition.
It was not feasible to relate our metric to genetic polymorphisms, since these are ethnically distributed and 
are not anticipated in an ethnically homogeneous population such as ours. Furthermore, genetic variation only 
explains a minor part of interindividual variability in SULT  activity15.
Thus, as a general caveat, PSI may reflect a number of variable pharmacokinetic processes that influence 
phenol sulfonation, such as cofactor availability or variation in alternative metabolic pathways like glucuron-
ide conjugation. It will not give us mechanistic information, but it will provide us an empirical measure of an 
individual’s sulfonator status for phenolic compounds, as previously hinted by RH Waring’s clinical research.
First insights into interindividual variability of PSI. Differences in sulfonation were not found 
between men and women. This is in sharp contrast with the documented sexual dimorphism of SULT expres-
sion in  rodents53 and in accordance with previous studies in humans that found no gender-related difference in 
the expression of various SULT isoforms in the  liver54 and in SULT1A1 enzymatic activity in liver  cytosols55. It 
suggests that stratification need not be done on the basis of gender for pharmacokinetic investigations of drugs 
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that are SULT1A1 substrates. There were also no differences in PSI between women on and off oral contracep-
tives, suggesting: (1) no influence of menstrual cycle hormonal fluctuations on sulfonation, (2) no relevant inhi-
bition of sulfonation of a single therapeutic dose of paracetamol by oral contraceptives, in contrast with previous 
in vitro and in vivo  results47,56. Obviously, these data will have to be confirmed in a larger population sample.
In conclusion, SULT phenotyping using paracetamol as a probe may provide a useful tool for implementing 
precision medicine initiatives for phenolic drugs mainly metabolized by SULT. To the best of our knowledge, 
our study constitutes the first attempt to standardise a phenotyping method that provides an in vivo empirical 
measure of an individual’s sulfonator status. It is a simple non-invasive method requiring urine spot samples, 
using the safe and convenient paracetamol as a probe drug, and with low intraindividual coefficient of variation.
To gain further knowledge on PSI, we are now studying a population of patients with chronic disease, with 
different comorbidities and environmental exposures, and under different drugs. We expect that analysing the 
interindividual variation in this population will provide new insights into our metric as, among other observa-
tions, we record variation in PSI for patients treated with known inhibitors/inducers of the enzyme or in relation 
to liver and other states of disease.
Data availability
The datasets generated and analysed during the current study are available from the corresponding author on 
reasonable request.
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